Key result
Selective NaV1.5 inhibition reveals NaV1.5 mediates ~92% of left ventricular sodium current.
Why the study?
Although Na V 1.5 is the primary cardiac voltage-gated sodium channel isoform, the composition and functional contributions of non-Na V 1.5 isoforms in the heart remain unclear.
Does selective pharmacological inhibition of NaV1.5 and non-NaV1.5 isoforms reveal chamber-specific differences in sodium current composition and cardiac excitability in a chemical-genetic mouse model?
Does selective pharmacological inhibition of NaV1.5 and non-NaV1.5 isoforms reveal chamber-specific differences in sodium current composition and cardiac excitability in a chemical-genetic mouse model?
This study demonstrates a chamber-specific voltage-gated sodium channel isoform landscape in the murine heart—with the right ventricle having the lowest NaV1.5 reserve and highest sensitivity to NaV1.5 blockade—providing a molecular explanation for the right ventricular phenotype of Brugada syndrome and highlighting non-NaV1.5 isoforms as potential chamber-specific therapeutic targets.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chamber-specific NaV contributions in mice may explain regional arrhythmia phenotypes; leaves open non-NaV1.5 isoforms as human therapeutic targets.
BACKGROUND: Na V (voltage-gated sodium) channels drive cardiac excitability. Although Na V 1.5 is the primary cardiac isoform, the composition and functional contributions of non-Na V 1.5 isoforms in the heart remain unclear. METHODS: Here, we developed a chemical-genetic mouse model (Na V 1.5 GX/GX ) in which Na V 1.5 can be selectively and reversibly inhibited by acyl- and aryl-sulfonamide compounds (GX [acyl- and aryl-sulfonamide compounds typically denoted by the name GX-### and associated items] drugs). Cardiac activity was assessed by electrocardiograms in vivo, and optical mapping was used for imaging of ex vivo hearts. Whole-cell voltage-clamp in tandem with validated toxins and isoform-selective inhibitors were used to examine sodium current composition. RESULTS: Na V 1.5 GX/GX mice exhibited normal cardiac function at baseline, but acute GX drug administration caused profound conduction defects and arrhythmias. Whole-heart optical mapping revealed dose-dependent chamber-specific sensitivity to Na V 1.5 inhibition, with the right ventricle being the most sensitive, followed by the left ventricle, left atrium, and right atrium. Patch-clamp recordings of isolated cardiomyocytes with application of Na V isoform-selective inhibitors showed that Na V 1.5 contributed 93% of sodium current in the left ventricle, 79% in the right ventricle, and 78% in the atria. Non-Na V 1.5 isoforms were differentially enriched across chambers: Na V 1.8 in the left ventricle, Na V 1.1/1.3 in the right ventricle, and Na V 1.2/1.6/1.7 in the atria. CONCLUSIONS: These results reveal a surprising chamber-specific isoform landscape of cardiac sodium currents, which may underlie the right ventricular predominant phenotype of Brugada syndrome. These data highlight non-Na V 1.5 isoforms as potential mediators of chamber-specific cardiac pathologies and as pharmacological targets.
Clark et al. (2026) studied Cardiac excitability and arrhythmias. Selective pharmacological NaV1.5 inhibition (GX-674, GX-201, MRL5) and isoform-selective blockers (TTX, GIIIB, VSTx-3) vs. Wild-type (NaV1.5+/+) mice or baseline vehicle control was evaluated on Proportion of baseline inward sodium current (INa) conducted by NaV1.5 in left ventricular cardiomyocytes inhibited by 500 nM GX-674. Selective NaV1.5 inhibition revealed that NaV1.5 contributes 92.3% of sodium current in the left ventricle, 79.4% in the right ventricle, and 77.9% in the atria of engineered mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: